Logo image of CLPT

CLEARPOINT NEURO INC (CLPT) Stock Fundamental Analysis

NASDAQ:CLPT - Nasdaq - US18507C1036 - Common Stock - Currency: USD

10.82  -0.1 (-0.92%)

After market: 10.8 -0.02 (-0.18%)

Fundamental Rating

4

Overall CLPT gets a fundamental rating of 4 out of 10. We evaluated CLPT against 187 industry peers in the Health Care Equipment & Supplies industry. CLPT has a great financial health rating, but its profitability evaluates not so good. CLPT is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLPT had negative earnings in the past year.
CLPT had a negative operating cash flow in the past year.
CLPT had negative earnings in each of the past 5 years.
In the past 5 years CLPT always reported negative operating cash flow.
CLPT Yearly Net Income VS EBIT VS OCF VS FCFCLPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of CLPT (-69.15%) is worse than 73.26% of its industry peers.
CLPT has a worse Return On Equity (-104.04%) than 64.17% of its industry peers.
Industry RankSector Rank
ROA -69.15%
ROE -104.04%
ROIC N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
CLPT Yearly ROA, ROE, ROICCLPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Gross Margin of CLPT (61.20%) is better than 60.96% of its industry peers.
In the last couple of years the Gross Margin of CLPT has declined.
CLPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
CLPT Yearly Profit, Operating, Gross MarginsCLPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

CLPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLPT has been increased compared to 1 year ago.
The number of shares outstanding for CLPT has been increased compared to 5 years ago.
CLPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLPT Yearly Shares OutstandingCLPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CLPT Yearly Total Debt VS Total AssetsCLPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

CLPT has an Altman-Z score of 8.56. This indicates that CLPT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CLPT (8.56) is better than 88.77% of its industry peers.
There is no outstanding debt for CLPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.56
ROIC/WACCN/A
WACC8.85%
CLPT Yearly LT Debt VS Equity VS FCFCLPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 3.53 indicates that CLPT has no problem at all paying its short term obligations.
CLPT has a better Current ratio (3.53) than 62.57% of its industry peers.
CLPT has a Quick Ratio of 2.57. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
CLPT has a Quick ratio (2.57) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.53
Quick Ratio 2.57
CLPT Yearly Current Assets VS Current LiabilitesCLPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.52% over the past year.
CLPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.23%.
CLPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.85% yearly.
EPS 1Y (TTM)9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.5%
Revenue 1Y (TTM)23.23%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%11.07%

3.2 Future

The Earnings Per Share is expected to grow by 3.12% on average over the next years.
Based on estimates for the next years, CLPT will show a very strong growth in Revenue. The Revenue will grow by 32.35% on average per year.
EPS Next Y-12.2%
EPS Next 2Y1.9%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue Next Year19.83%
Revenue Next 2Y23.62%
Revenue Next 3Y32.35%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLPT Yearly Revenue VS EstimatesCLPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 2031 2032 50M 100M 150M 200M
CLPT Yearly EPS VS EstimatesCLPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLPT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLPT Price Earnings VS Forward Price EarningsCLPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLPT Per share dataCLPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.9%
EPS Next 3Y3.12%

More info and screens

0

5. Dividend

5.1 Amount

CLPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARPOINT NEURO INC

NASDAQ:CLPT (8/8/2025, 8:00:00 PM)

After market: 10.8 -0.02 (-0.18%)

10.82

-0.1 (-0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12
Inst Owners34.73%
Inst Owner Change-0.9%
Ins Owners5.34%
Ins Owner Change24.02%
Market Cap305.88M
Analysts82.5
Price Target29.58 (173.38%)
Short Float %8.01%
Short Ratio5.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.43%
Min EPS beat(2)-34.8%
Max EPS beat(2)-20.05%
EPS beat(4)1
Avg EPS beat(4)-9.11%
Min EPS beat(4)-34.8%
Max EPS beat(4)20.24%
EPS beat(8)4
Avg EPS beat(8)-4.83%
EPS beat(12)7
Avg EPS beat(12)-1.91%
EPS beat(16)8
Avg EPS beat(16)-2.7%
Revenue beat(2)1
Avg Revenue beat(2)-2.99%
Min Revenue beat(2)-7.42%
Max Revenue beat(2)1.45%
Revenue beat(4)3
Avg Revenue beat(4)0.37%
Min Revenue beat(4)-7.42%
Max Revenue beat(4)5.11%
Revenue beat(8)5
Avg Revenue beat(8)-0.8%
Revenue beat(12)7
Avg Revenue beat(12)-0.89%
Revenue beat(16)9
Avg Revenue beat(16)0.47%
PT rev (1m)0%
PT rev (3m)16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-21.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.49
P/FCF N/A
P/OCF N/A
P/B 15.3
P/tB 15.66
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS1.14
BVpS0.71
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.15%
ROE -104.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.2%
FCFM N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
F-Score5
Asset Turnover1.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.52%
Cap/Sales 1.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.53
Quick Ratio 2.57
Altman-Z 8.56
F-Score5
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)225.04%
Cap/Depr(5y)185.37%
Cap/Sales(3y)3.62%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.5%
EPS Next Y-12.2%
EPS Next 2Y1.9%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue 1Y (TTM)23.23%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%11.07%
Revenue Next Year19.83%
Revenue Next 2Y23.62%
Revenue Next 3Y32.35%
Revenue Next 5YN/A
EBIT growth 1Y-3.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.77%
EBIT Next 3Y25.55%
EBIT Next 5YN/A
FCF growth 1Y37.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.82%
OCF growth 3YN/A
OCF growth 5YN/A